AULBIO is engaged globally in the research/development and commercialization of highly technical company located in South Korea. We have developed an optimal drug delivery system using injectable biodegradable microspheres. AULBIO's Long-acting injectable microsphere technology is a very simple process, and has excellent reproducibility. We deal with bio-peptide drugs, and are designed to maintain its efficacy for 1 to 6 months or longer. AULBIO is focusing on the fields of diabetes, obesity and prostate cancer using drug delivery technology with global competitiveness. Specially, we have been researching semaglutide, tirzepatide, and exenatide long acting injectables for treatment of obesity and diabetes respectively.